211 related articles for article (PubMed ID: 36270754)
1. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
Lowry N; Cowden F; Day E; Gilvarry E; Johnstone S; Murray R; Kelleher M; Mitcheson L; Marsden J
BMJ Open; 2022 Oct; 12(10):e067194. PubMed ID: 36270754
[TBL] [Abstract][Full Text] [Related]
2. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
[TBL] [Abstract][Full Text] [Related]
3. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.
Marsden J; Kelleher M; Gilvarry E; Mitcheson L; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hardy W; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Vanderwaal R; Wareham A; Hughes D; Hoare Z
EClinicalMedicine; 2023 Dec; 66():102311. PubMed ID: 38045803
[TBL] [Abstract][Full Text] [Related]
4. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.
Winhusen T; Lofwall M; Jones HE; Wilder C; Lindblad R; Schiff DM; Wexelblatt S; Merhar S; Murphy SM; Greenfield SF; Terplan M; Wachman EM; Kropp F; Theobald J; Lewis M; Matthews AG; Guille C; Silverstein M; Rosa C
Contemp Clin Trials; 2020 Jun; 93():106014. PubMed ID: 32353544
[TBL] [Abstract][Full Text] [Related]
5. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.
Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M;
BMJ Open; 2020 Jul; 10(7):e034389. PubMed ID: 32737087
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series.
Peckham AM; Kehoe LG; Gray JR; Wakeman SE
J Subst Abuse Treat; 2021 Jul; 126():108316. PubMed ID: 34116808
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
[TBL] [Abstract][Full Text] [Related]
10. The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients.
Guillery SPE; Reiners S; Fahrner M; Enge S; Hellweg R; Kunte H; Kronenberg G
Addict Biol; 2023 May; 28(5):e13275. PubMed ID: 37186443
[TBL] [Abstract][Full Text] [Related]
11. The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: Protocol for an Observational Prospective Study.
Langlois J; Nolan S; Dickhout P; Cui Z; Paterson J; Fairbairn N; Socías ME
Subst Use Addctn J; 2024 Apr; 45(2):176-180. PubMed ID: 38254287
[TBL] [Abstract][Full Text] [Related]
12. The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.
D'Onofrio G; Hawk KF; Herring AA; Perrone J; Cowan E; McCormack RP; Dziura J; Taylor RA; Coupet E; Edelman EJ; Pantalon MV; Owens PH; Martel SH; O'Connor PG; Van Veldhuisen P; DeVogel N; Huntley K; Murphy SM; Lofwall MR; Walsh SL; Fiellin DA
Contemp Clin Trials; 2021 May; 104():106359. PubMed ID: 33737199
[TBL] [Abstract][Full Text] [Related]
13. Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting.
Wong JSH; Masson S; Huang A; Romm D; Fong M; Porter T; Sharifi N; Azar P; Mathew N
J Correct Health Care; 2022 Dec; 28(6):368-371. PubMed ID: 36342953
[TBL] [Abstract][Full Text] [Related]
14. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
[TBL] [Abstract][Full Text] [Related]
15. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
17. Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.
Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
J Addict Med; 2019; 13(6):442-449. PubMed ID: 30844878
[TBL] [Abstract][Full Text] [Related]
18. Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series.
Hansen ER; South AM; Lofwall MR; Fanucchi LC
J Addict Med; 2024 Jan-Feb 01; 18(1):65-67. PubMed ID: 37874645
[TBL] [Abstract][Full Text] [Related]
19. Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.
Boyett B; Nadipelli VR; Solem CT; Chilcoat H; Bickel WK; Ling W
J Addict Med; 2023 Mar-Apr 01; 17(2):182-189. PubMed ID: 36111991
[TBL] [Abstract][Full Text] [Related]
20. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
